Progyny, Inc. (NASDAQ:PGNY) Chairman David J. Schlanger Sells 1,000 Shares

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) Chairman David J. Schlanger sold 1,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $37.52, for a total transaction of $37,520.00. Following the transaction, the chairman now owns 83,631 shares in the company, valued at $3,137,835.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Progyny Trading Up 0.2 %

PGNY traded up $0.08 during midday trading on Wednesday, reaching $35.75. The company's stock had a trading volume of 900,859 shares, compared to its average volume of 816,407. Progyny, Inc. has a 1 year low of $29.44 and a 1 year high of $44.95. The stock's 50-day moving average is $37.81 and its 200-day moving average is $35.65. The firm has a market capitalization of $3.45 billion, a price-to-earnings ratio of 57.66, a PEG ratio of 1.51 and a beta of 1.48.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.04. Progyny had a return on equity of 12.64% and a net margin of 5.70%. The company had revenue of $269.94 million for the quarter, compared to the consensus estimate of $274.08 million. During the same quarter in the prior year, the business posted $0.03 EPS. The firm's quarterly revenue was up 26.0% compared to the same quarter last year. As a group, equities research analysts forecast that Progyny, Inc. will post 0.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PGNY shares. Leerink Partnrs reissued an "outperform" rating on shares of Progyny in a research note on Monday, February 26th. SVB Leerink assumed coverage on Progyny in a research note on Monday, February 26th. They issued an "outperform" rating and a $49.00 price target for the company. Barclays started coverage on shares of Progyny in a research report on Wednesday, January 3rd. They issued an "overweight" rating and a $48.00 target price for the company. Truist Financial reduced their price target on shares of Progyny from $47.00 to $46.00 and set a "buy" rating on the stock in a research report on Wednesday, February 28th. Finally, KeyCorp decreased their price target on shares of Progyny from $45.00 to $43.00 and set an "overweight" rating for the company in a research note on Wednesday, February 28th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $48.30.

Hedge Funds Weigh In On Progyny

Large investors have recently modified their holdings of the stock. RiverPark Advisors LLC increased its stake in Progyny by 54.0% during the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company's stock valued at $40,000 after purchasing an additional 374 shares in the last quarter. Rockefeller Capital Management L.P. grew its holdings in shares of Progyny by 3,119.2% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,674 shares of the company's stock valued at $50,000 after buying an additional 1,622 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Progyny during the third quarter valued at approximately $53,000. Lazard Asset Management LLC raised its holdings in Progyny by 45.2% in the 4th quarter. Lazard Asset Management LLC now owns 1,763 shares of the company's stock worth $54,000 after acquiring an additional 549 shares during the last quarter. Finally, International Assets Investment Management LLC purchased a new position in Progyny in the 3rd quarter worth approximately $58,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.